Overview of
The Andrew Cooke
Rare Lung Cancer Compassionate Use Program
Because of our Generous Supporters, ICAN patients involved in
The Andrew Cooke Rare Lung Cancer Compassionate Use Program
have access to the following information services:
- Direct Navigation of Exon 20 Insertion Cases, both EGFR Exon 20 Insertions and HER2 Exon 20 Insertions;
- Patient-Reported Outcomes Surveys of our Exon 20 and Rare Cancers Communities;
- Cutting-Edge Research at Top Laboratories Focusing on Exon 20 Resistance Mutations
- Public Policy Initiatives to Accelerate the Rare Lung Cancer Treatment Pipeline
- Health Information Technology Initiatives
- National, Global, and Country-by Country Sequencing and Profiling Campaigns to Identify Exon 20 Insertions and Point Mutations on Diagnosis.
The Andrew Cooke Rare Lung Cancer Compassionate Use Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
For more information about this special program, please click on.....
ICAN is currently working on The Andrew Cooke Rare Lung Cancer Compassionate Use Program. We are working to put together a Family and Friends Advisory Council for the The Andrew Cooke Rare Lung Cancer Compassionate Use Program. If interested, please email us at Andrew.Cooke.Program@askican.org.
If you would like to become involved as a donor and supporter or a member of our Cancer Research Literature team as a Research Team Leader (medical school students, physicians, nurses, and post-docs only please), you may reach us at Andrew.Cooke.Program@askican.org.
Federal Tax I.D.: EIN 86-0818253